 The purpose of this study is to evaluate the safety and tolerability, identify the Maximum Tolerated Dose MTD or the Minimum Efficacious Dose MED and designate a dose level for Phase 2. Also characterize the immunogenicity, pharmacokinetic profile, and biomarker serum levels of ALT-803 in treated patients. 